← All trials
NCT05195242
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2020
- Primary completion
- Jun 20, 2021
- Completion date
- Jun 30, 2021
- First posted
- Jan 18, 2022
- Last posted
- Jun 27, 2022
- Enrollment
- 445
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Karolinska InstituteLead sponsor
- Aarhus UniversityCollaborator
- Aalborg UniversityCollaborator
- Scandinavian Critical Care Trials GroupCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- Karolinska InstituteReponsible party - principal investigator
- Karolinska InstituteStudy chair
- Karolinska InstituteStudy director
- Stockholm South General HospitalCollaborator
- Linkoping UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.